human
cytomegaloviru
cmv
caus
signific
diseas
immunocompromis
patient
seriou
birth
defect
acquir
utero
avail
cmv
antivir
target
viral
dna
polymeras
signific
toxic
suffer
resist
new
drug
target
differ
pathway
would
benefici
anthraquinon
emodin
propos
inhibit
herp
simplex
viru
block
viral
nucleas
emodin
relat
anthraquinon
also
report
inhibit
cmv
present
studi
emodin
reduc
cmv
infecti
yield
ec
cytotox
concentr
twofold
higher
relat
anthraquinon
acid
blue
alizarin
violet
r
inhibit
cmv
high
concentr
also
cytotox
howev
atanyl
blue
prl
inhibit
infecti
yield
cmv
ec
significantli
cytotox
concentr
atanyl
blue
prl
reduc
cmv
infect
inhibit
spread
ad
one
h
infect
dramat
reduc
cmv
immedi
earli
protein
express
block
viral
dna
synthesi
howev
antivir
activ
ad
h
infect
interestingli
atanyl
blue
prl
inhibit
nucleas
activ
purifi
cmv
protein
ic
result
indic
atanyl
blue
prl
target
earli
postentri
event
cmv
replic
suggest
may
act
inhibit
make
novel
cmv
inhibitor
compound
may
provid
valuabl
insight
molecular
event
occur
earliest
time
postinfect
serv
lead
structur
antivir
develop
human
cytomegaloviru
cmv
caus
spectrum
diseas
immun
compromis
patient
includ
retin
hiv
patient
pneumon
transplant
patient
seriou
birth
defect
character
sensorineur
hear
loss
sever
mental
retard
acquir
pregnanc
drug
current
licens
treatment
system
cmv
infect
limit
therapeut
effect
due
doselimit
toxic
prolong
therapi
often
result
resist
biron
none
approv
treatment
prevent
congenit
infect
thu
press
need
potent
less
toxic
therapeut
combat
cmv
infect
one
possibl
target
develop
novel
antivir
cmv
alkalin
nucleas
encod
gene
homolog
encod
known
herpesvirus
alkalin
nucleas
encod
herp
simplex
viru
type
necessari
effici
replic
cell
cultur
martinez
et
al
shao
et
al
impair
replic
link
defect
dna
process
capsid
stabil
capsid
nuclear
egress
martinez
et
al
porter
stow
shao
et
al
weller
et
al
recent
group
show
cmv
null
mutant
sever
compromis
replic
kuchta
et
al
least
one
function
cmv
like
similar
sinc
cmv
gene
function
complement
replic
defect
null
virus
gao
et
al
recent
studi
indic
nucleas
activ
import
neurovirul
mice
yet
larg
dispens
replic
cell
cultur
fujii
et
al
contrast
earlier
studi
indic
nucleas
activ
import
vitro
replic
sinc
allel
encod
function
nucleas
abl
complement
replic
null
mutant
virus
goldstein
weller
henderson
et
al
consist
nucleas
activ
play
import
role
vitro
vivo
recent
studi
found
anthraquinon
emodin
fig
inhibit
dnase
activ
vitro
block
replic
herp
simplex
viru
type
cell
cultur
reduc
viral
pathogenes
mous
model
hsiang
ho
xiong
et
al
earlier
report
indic
emodin
anthraquinon
deriv
also
cmv
inhibitori
activ
barnard
et
al
barnard
et
al
although
mechan
cmv
inhibit
studi
present
studi
anticmv
activ
emodin
three
relat
anthraqinon
atanyl
blue
prl
also
known
acid
blue
acid
blue
alizarin
violet
r
fig
evalu
atanyl
blue
prl
anticmv
activ
act
earli
postentri
stage
replic
atanyl
blue
prl
also
inhibit
nucleas
activ
suggest
potenti
mechan
action
activ
import
earli
cmv
replic
cycl
human
fibroblast
atcc
propag
modifi
eagl
medium
gibcobrl
supplement
fetal
calf
serum
hyclon
laboratori
iul
penicillin
mgl
streptomycin
gibcobrl
mem
cmv
gift
thoma
shenk
dai
wang
variant
cmv
strain
contain
marker
cassett
encod
green
fluoresc
protein
gfp
control
simian
viru
promot
insert
wang
shenk
cmv
variant
cmv
strain
town
contain
luciferas
express
cassett
control
synthet
promot
compos
seven
tetracyclin
oper
element
taatacontain
element
adenoviru
major
late
promot
initi
mous
tdt
gene
promot
insert
region
mcvoy
mocarski
express
relev
marker
protein
gfp
luciferas
encod
virus
detect
earli
hour
post
infect
hpi
virus
propag
cell
titer
describ
cui
et
al
cui
et
al
saccoccio
et
al
ganciclovir
purchas
invivogen
bay
provid
pharmaceut
tubigen
germani
emodin
atanyl
blue
prl
acid
blue
purchas
sigmaaldrich
co
alizarin
violet
r
purchas
mp
biomed
ganciclovir
dissolv
water
concentr
mm
remain
compound
solubil
dimethyl
sulfoxid
dmso
sigmaaldrich
stock
concentr
mm
compound
store
cmv
yield
determin
use
luciferasebas
assay
describ
previous
bhave
et
al
briefli
plate
contain
confluent
monolay
fibroblast
infect
low
input
multipl
luciferasetag
cmv
mcvoy
mocarski
incub
one
hour
variou
amount
test
compound
mem
ad
noviru
control
nodrug
control
consist
medium
contain
dmso
equal
maximum
amount
dmso
present
test
compound
assay
assay
plate
condit
assay
triplic
cultur
maintain
addit
media
chang
day
post
infect
dpi
supernat
well
transfer
blackwal
clearflatbottom
plate
contain
confluent
monolay
luciferas
activ
measur
h
later
use
steadyglo
luciferas
assay
reagent
promega
luciferas
activ
measur
rel
light
unit
rlu
use
biotek
synergi
ht
multimod
micropl
reader
data
normal
convert
rlu
percent
maximum
luminesc
experi
fit
fourparamet
curv
use
prism
graphpad
softwar
inc
determin
halfmaxim
effect
concentr
ec
test
compound
time
addit
studi
cultur
infect
describ
maintain
medium
compound
ad
differ
time
post
infect
compound
dilut
cultur
medium
ad
cultur
maintain
addit
media
chang
dpi
two
preincub
experi
conduct
conjunct
time
addit
studi
first
well
contain
uninfect
cell
incub
h
medium
contain
atanyl
blue
prl
wash
time
medium
remov
atanyl
blue
prl
cultur
infect
describ
maintain
day
medium
without
atanyl
blue
prl
second
higher
concentr
viru
inoculum
incub
h
medium
contain
atanyl
blue
prl
dilut
cultur
medium
ad
well
contain
cell
blackwal
clear
bottom
plate
contain
confluent
monolay
cell
incub
triplic
test
compound
describ
five
day
supernat
remov
celltiterglo
assay
reagent
promega
ad
well
luminesc
measur
rlu
describ
data
normal
fit
fourparamet
curv
determin
toxic
dose
td
test
compound
clearwal
clearbottom
plate
contain
confluent
monolay
cell
infect
gfpexpress
cmv
time
viru
infect
atanyl
blue
prl
mem
ad
achiev
variou
final
concentr
noviru
control
nodrug
control
consist
medium
contain
dmso
equal
maximum
amount
dmso
present
test
compound
assay
assay
plate
condit
assay
triplic
specifi
dpi
gfp
fluoresc
quantifi
rel
fluoresc
unit
rfu
use
biotek
synergi
ht
multimod
micropl
reader
use
calcul
ec
describ
experi
individu
gfpposit
cell
mark
photomicrograph
everi
two
day
use
nikon
eclips
uv
invert
microscop
measur
effect
atanyl
blue
prl
cmv
infect
cultur
plate
infect
cmv
concentr
empir
determin
result
well
becom
infect
group
replic
well
treat
time
infect
mem
contain
increas
concentr
atanyl
blue
prl
day
well
score
presenc
absenc
gfp
fluoresc
use
nikon
eclips
invert
microscop
percentag
posit
well
group
plot
vs
atanyl
blue
prl
concentr
ec
determin
describ
replic
cm
flask
contain
confluent
cell
mock
infect
infect
multipl
infect
moi
time
infect
replic
flask
adjust
final
concentr
atanyl
blue
prl
left
untreat
cell
replic
flask
harvest
daili
day
post
infect
analyz
immunoblot
describ
previous
ryckman
et
al
saccoccio
et
al
primari
antibodi
includ
mous
monoclon
millipor
dilut
mous
monoclon
rice
et
al
gift
jay
nelson
dilut
rabbit
polyclon
antisera
glycoprotein
b
gb
gift
larri
smith
vical
inc
dilut
secondari
antibodi
horseradish
peroxidaseconjug
polyclon
goat
antimous
goat
antirabbit
igg
thermofish
dilut
replic
cm
flask
contain
confluent
cell
mock
infect
infect
moi
one
set
flask
contain
mem
throughout
experi
second
contain
mem
atanyl
blue
prl
time
infect
third
set
contain
mem
time
infect
hpi
mem
replac
mem
contain
atanyl
blue
prl
cell
replic
flask
harvest
hpi
trypsin
dna
extract
describ
previous
mcvoy
et
al
dna
precipit
dissolv
water
dna
concentr
measur
use
nanodrop
spectrophotomet
qrtpcr
perform
virginia
commonwealth
univers
nucleic
acid
research
facil
use
viia
sequenc
detect
system
life
technolog
univers
pcr
master
mix
reagent
life
technolog
forward
primer
atcca
revers
primer
probe
vicaccgcaacaagattmgbnfq
deriv
exon
five
gene
describ
previous
boppana
et
al
reaction
contain
ng
dna
forward
revers
primer
probe
cycl
condit
min
min
cycl
min
ribosom
rna
measur
use
primer
provid
assay
reagent
endogen
control
determin
rel
cmv
dna
copiescel
reaction
perform
triplic
recombin
induc
express
e
coli
ly
purifi
use
method
modifi
previous
describ
kuchta
et
al
express
vector
wt
kuchta
et
al
modifi
contain
ntermin
sequenc
encod
two
tandem
histidin
tag
accomplish
anneal
synthet
linker
ttcggaggccaccaccaccaccaccacagcagcggcagagaaaacctgtatttt
ggtggtggtggtggtggcctccgaactgcgggtgacgccaagctctagaatggt
ligat
ndeixhoirestrict
wt
make
plasmid
wt
e
coli
ly
cell
contain
wt
cultur
induc
iptg
hr
describ
previous
kuchta
et
al
bacteria
liter
cultur
pellet
snap
frozen
liquid
nitrogen
store
frozen
cell
thaw
ice
buffer
mm
triscl
ph
mm
imidazol
glycerol
mm
nacl
extract
ultrason
disrupt
clarifi
centrifug
x
g
supernat
dilut
buffer
appli
akta
fast
protein
liquid
chromatographi
system
equip
ml
niagaros
column
ninta
superflow
qiagen
equilibr
buffer
column
wash
ml
buffer
contain
mm
imidazol
elut
ml
linear
gradient
buffer
contain
mm
imidazol
fraction
contain
materi
reactiv
monoclon
antibodi
immunoblot
analysi
combin
dialyz
overnight
buffer
mm
triscl
ph
mm
nacl
edta
mm
glycerol
appli
ml
mono
q
column
equilibr
buffer
column
wash
ml
buffer
protein
elut
ml
linear
gradient
buffer
contain
mm
kcl
oneml
fraction
assay
presenc
nucleas
activ
describ
immunoblot
monoclon
antibodi
present
fraction
elut
mm
kcl
store
month
two
assay
use
measur
inhibit
nucleas
activ
first
measur
combin
endonucleas
exonucleas
activ
releas
trichloroacet
acid
tca
solubleradioact
uniformli
clabel
e
coli
duplex
dna
describ
previous
hoffmann
cheng
unit
enzym
activ
defin
amount
enzym
requir
digest
ng
label
dna
tcasolubl
min
variou
compound
concentr
ad
reaction
mix
assay
initi
addit
purifi
unit
control
reaction
contain
dmso
without
compound
incub
min
reaction
termin
addit
tca
final
concentr
unlabel
sonic
denatur
salmon
sperm
dna
carrier
second
assay
use
doublyquench
fluoresc
hairpin
probe
measur
predominantli
exonucleas
activ
fluoresc
reson
emiss
transfer
fret
assay
synthet
oligonucleotid
label
end
fam
fluorophor
nucleotid
zen
quencher
end
iowa
black
dark
quencher
idt
probe
heat
min
quench
ice
form
hairpin
contain
overhang
exonucleolyt
releas
famlabel
nucleotid
result
fluoresc
assay
contain
nm
hairpin
dna
substrat
incub
purifi
enzym
unit
describ
min
termin
addit
edta
mm
final
concentr
aliquot
transfer
triplic
roundbottom
blackwal
pate
rfu
measur
use
spectramax
fluoromet
molecular
devic
control
contain
substrat
incub
without
enzym
use
determin
background
valu
subtract
experiment
read
data
inhibitor
concentr
express
percentag
maxim
activ
obtain
untreat
control
dna
plu
enzym
dmso
mean
one
standard
deviat
three
independ
assay
plot
fit
fourparamet
curv
determin
inhibitori
concentr
ic
structur
compound
sketch
use
sybylx
tripo
inc
charg
assign
subject
energi
minim
tripo
forcefield
iter
termin
gradient
previous
report
model
complex
substrat
dna
kuchta
et
al
use
perform
dock
studi
use
gold
bind
site
defin
encompass
atom
within
radiu
locat
center
activ
site
default
genet
algorithm
paramet
use
total
solut
per
compound
gener
earli
termin
constraint
plausibl
bind
mode
identifi
use
hint
forcefield
kellogg
abraham
ligand
favor
bind
conform
complex
protein
subject
minim
powel
minim
iter
termin
gradient
remov
steric
clash
optim
proteinligand
interact
within
activ
site
explor
anticmv
activ
emodin
relat
anthraquinon
fig
luciferasebas
yield
reduct
assay
bhave
et
al
use
cell
infect
luciferasetag
cmv
moi
increas
concentr
emodin
ad
hpi
five
dpi
viru
yield
measur
transfer
cultur
supernat
uninfect
cell
measur
luciferas
activ
cultur
h
later
cytotox
evalu
ad
concentr
emodin
uninfect
cell
five
day
measur
intracellular
atp
level
function
luciferas
activ
use
celltiterglo
assay
luciferas
data
use
determin
emodin
effect
concentr
ec
anticmv
activ
cytotox
dose
td
tabl
ec
confirm
emodin
inhibit
cmv
replic
emodin
concentr
less
twofold
higher
cytotox
fig
tabl
thu
emodin
anticmv
activ
like
nonspecif
aris
simpli
due
toxic
effect
host
cell
sever
anthraquinon
deriv
previous
report
possess
anticmv
activ
barnard
et
al
atanyl
blue
prl
acid
blue
alizarin
violet
r
fig
evalu
use
assay
describ
ec
acid
blue
alizarin
violet
r
high
respect
close
correspond
cytotox
fig
c
tabl
thu
less
toxic
emodin
two
compound
also
appear
lack
virusspecif
inhibitori
activ
contrast
atanyl
blue
prl
exhibit
anticmv
activ
similar
emodin
ec
cytotox
similar
acid
blue
alizarin
violet
r
td
fig
tabl
result
select
index
si
tabl
suggest
atanyl
blue
prl
cmv
inhibitori
activ
determin
impact
atanyl
blue
prl
viral
gene
express
cell
cultur
infect
cmv
genet
engin
express
gfp
moi
use
order
initi
infect
approxim
twothird
cell
cultur
increas
concentr
atanyl
blue
prl
ad
immedi
infect
gfp
fluoresc
quantifi
four
dpi
atanyl
blue
prl
reduc
gfp
express
infect
cell
doserespons
fashion
fig
ec
calcul
gfp
data
compar
luciferasebas
anticmv
activ
tabl
similar
experi
conduct
measur
effect
atanyl
blue
prl
cmv
spread
case
cultur
infect
moi
cell
initi
infect
gfp
measur
dpi
allow
progeni
time
spread
remain
cell
cultur
atanyl
blue
prl
reduc
gfp
express
doserespons
fashion
experi
well
fig
ec
ident
obtain
higher
moi
experi
visual
effect
atanyl
blue
prl
cmv
spread
cultur
infect
moi
either
mock
treat
dmso
treat
atanyl
blue
prl
dpi
individu
gfpposit
cell
identifi
mark
could
reloc
photograph
everi
two
day
thereaft
absenc
inhibitor
gfpposit
foci
expand
form
larg
syncytia
presum
infect
subsequ
fuse
adjac
cell
contrast
presenc
atanyl
blue
prl
gfpposit
foci
expand
cell
fig
note
atanyl
blue
prl
elimin
gfp
express
observ
dpi
greatli
reduc
number
gfpposit
cell
per
well
compar
vehicl
control
data
shown
suggest
possibl
atanyl
blue
prl
reduc
cmv
infect
promot
abort
infect
fail
reach
stage
gfp
express
quantifi
impact
atanyl
blue
prl
cmv
infect
cell
plate
infect
gfptag
cmv
dilut
empir
determin
result
infect
well
condit
infect
well
receiv
one
two
infecti
virion
increas
concentr
atanyl
blue
prl
ad
replic
set
well
day
well
score
absenc
presenc
gfp
indic
success
viral
entri
gene
express
although
drug
control
confirm
well
receiv
least
one
infecti
viru
led
gfp
express
dpi
percentag
gfpposit
well
treat
atanyl
blue
prl
decreas
dosedepend
manner
ec
calcul
data
similar
obtain
viru
yield
gfp
express
assay
fig
tabl
suggest
atanyl
blue
prl
block
cmv
earli
stage
viral
replic
cycl
better
determin
stage
viral
replic
affect
atanyl
blue
prl
compound
ad
viru
cell
prior
infect
cell
viru
time
infect
infect
cell
differ
time
post
infect
base
result
shown
fig
concentr
atanyl
blue
prl
select
lowest
concentr
result
effect
inhibit
viral
yield
ganciclovir
inhibit
cmv
dna
synthesi
bay
inhibit
cmv
dna
packag
buerger
et
al
also
test
known
lateact
control
expect
ganciclovir
bay
could
ad
late
hpi
still
substanti
reduc
viru
yield
detect
day
contrast
antivir
activ
atanyl
blue
prl
lost
ad
hpi
later
fig
refin
window
activ
experi
repeat
atanyl
blue
prl
ad
hpi
atanyl
blue
prl
ineffect
ad
hpi
retain
partial
effect
ad
hpi
fig
result
suggest
atanyl
blue
prl
inhibit
import
step
viral
replic
suffici
complet
hpi
howev
viral
attach
entri
larg
complet
time
possibl
viral
particl
inactiv
exposur
atanyl
blue
prl
attach
entri
test
possibl
viral
inoculum
preincub
atanyl
blue
prl
h
serial
dilut
ad
cell
pretreat
impact
viral
yield
five
day
later
fig
indic
transient
exposur
effect
concentr
atanyl
blue
prl
irrevers
inactiv
infect
virion
similar
experi
cell
pretreat
atanyl
blue
prl
h
wash
prior
infect
remov
atanyl
blue
prl
pretreat
cell
impact
viral
yield
five
day
later
fig
indic
atanyl
blue
prl
induc
chang
cellular
environ
limit
subsequ
viral
entri
replic
follow
entri
cmv
genom
deposit
within
nucleu
abund
transcript
initi
major
immedi
earli
promot
miep
result
rapid
accumul
sever
immedi
earli
ie
protein
turn
requir
express
earli
protein
includ
factor
requir
viral
dna
synthesi
turn
trigger
express
late
protein
requir
assembl
progeni
virion
time
addit
studi
suggest
atanyl
blue
prl
may
block
replic
prior
ie
protein
express
address
question
cell
infect
presenc
absenc
atanyl
blue
prl
assay
immuoblot
determin
level
ie
protein
shown
figur
atanyl
blue
prl
profoundli
reduc
level
cmv
ie
protein
throughout
cours
infect
level
earli
protein
late
protein
gb
also
reduc
data
shown
hpi
cmv
genom
circular
initi
stage
dna
replic
begun
howev
signific
amplif
cmv
dna
occur
hpi
mcvoy
adler
addit
atanyl
blue
prl
hpi
impact
yield
strongli
suggest
atanyl
blue
prl
affect
cmv
dna
synthesi
inhibit
viral
dna
polymeras
replic
factor
directli
determin
impact
atanyl
blue
prl
cmv
dna
synthesi
cmvinfect
cultur
either
left
untreat
treat
atanyl
blue
prl
time
infect
start
hpi
replic
cultur
harvest
hpi
rel
copi
number
intracellular
cmv
dna
determin
qpcr
untreat
cultur
cmv
dna
replic
began
hpi
copi
number
increas
steadili
thereaft
fig
howev
atanyl
blue
prl
present
time
infect
cmv
dna
copi
number
remain
low
throughout
time
cours
addit
atanyl
blue
prl
hpi
delay
prevent
onset
cmv
dna
synthesi
copi
number
began
increas
hpi
exceed
mocktreat
control
hpi
fig
result
confirm
atanyl
blue
prl
directli
inhibit
viral
dna
synthes
inhibit
viral
alkalin
nucleas
emodin
propos
mechan
emodin
antivir
activ
hsiang
ho
prior
studi
express
purifi
cmv
alkalin
nucleas
character
nucleas
activ
vitro
kuchta
et
al
determin
atanyl
blue
prl
inhibit
nucleas
activ
recombin
perform
two
differ
assay
first
measur
effect
increas
concentr
inhibitor
abil
purifi
degrad
uniformli
label
dna
substrat
tcasolubl
form
less
assay
measur
combin
endonucleas
exo
activ
hoffmann
cheng
atanyl
blue
prl
inhibit
releas
solubl
radioact
ic
fig
contrast
relat
compound
acid
blue
littl
effect
nucleas
activ
concentr
higher
ic
second
assay
use
fret
assay
measur
remov
label
fluorophor
internallyquench
hairpin
dna
substrat
exonucleas
activ
assay
atanyl
blue
prl
inhibit
nucleas
activ
ic
acid
blue
littl
inhibitori
activ
ic
fig
result
confirm
atanyl
blue
prl
inhibit
nucleas
activ
purifi
anthraquinon
anthraquinon
deriv
bioactiv
compound
found
extract
deriv
bacteria
fungi
lichen
plant
number
compound
class
shown
inactiv
inhibit
entri
andor
replic
wide
varieti
virus
includ
herpesvirus
pseudorabi
viru
varicella
zoster
viru
retrovirus
includ
hiv
vesicular
stomat
viru
influenza
viru
parainfluenza
viru
vaccinia
viru
sar
coronaviru
hepat
b
viru
polioviru
coxsackieviru
andersen
et
al
cohen
et
al
esposito
et
al
esposito
et
al
higuchi
et
al
ho
et
al
liu
et
al
schinazi
et
al
schwarz
et
al
sempl
et
al
shuangsuo
et
al
sydiski
et
al
varieti
mechan
describ
includ
inactiv
disrupt
viral
envelop
alv
et
al
andersen
et
al
sydiski
et
al
disrupt
virionreceptor
interact
ho
et
al
disrupt
ion
channel
schwarz
et
al
inhibit
host
protein
kinas
battistutta
et
al
yim
et
al
inhibit
revers
transcriptas
rnase
h
esposito
et
al
esposito
et
al
higuchi
et
al
schinazi
et
al
emodin
certain
anthraquinon
deriv
report
anticmv
activ
barnard
et
al
barnard
et
al
recent
studi
found
emodin
activ
replic
cell
cultur
therapeut
benefit
mous
model
hsv
pathogenesi
hsiang
ho
xiong
et
al
studi
prompt
investig
anticmv
activ
emodin
relat
anthraquinon
deriv
ec
emodin
inhibit
cmv
studi
remark
similar
report
barnard
et
al
barnard
et
al
tabl
howev
high
toxic
result
low
si
studi
tabl
suggest
emodin
cmv
inhibit
like
aris
nonspecif
disrupt
cellular
metabol
process
rather
inhibit
process
uniqu
requir
viru
replic
subsequ
studi
barnard
et
al
examin
anticmv
activ
sever
anthraquinon
deriv
barnard
et
al
acid
blue
alizarin
violet
r
report
ec
unabl
confirm
result
assay
acid
blue
alizarin
violet
r
ec
si
tabl
respect
suggest
lack
specif
antivir
activ
howev
ec
td
si
atanyl
blue
prl
respect
similar
report
barnard
et
al
barnard
et
al
tabl
present
studi
extend
previou
find
demonstr
atanyl
blue
prl
impair
cmv
infect
sever
reduc
ie
gene
express
rapid
abund
accumul
ie
protein
activ
transcript
miep
crucial
drive
cmvinfect
cell
forward
lytic
replic
cycl
convers
repress
meip
lead
abort
infect
certain
cell
type
may
promot
establish
latenc
repress
chromatin
miep
thought
occur
default
upon
deliveri
viral
genom
nucleu
ioudinkova
et
al
reev
et
al
reev
et
al
sinclair
order
enter
lytic
replic
viral
tegument
protein
must
traffic
nucleu
act
derepress
ie
transcript
induc
degrad
daxx
saffert
kalejta
atanyl
blue
prl
could
interfer
ie
protein
express
point
attach
ie
transcriptiontransl
exposur
inoculum
inhibitori
dose
atanyl
blue
prl
prior
infect
impact
viral
yield
suggest
atanyl
blue
prl
block
viral
entri
directli
interact
irrevers
inactiv
virion
moreov
atanyl
blue
prl
retain
signific
potenc
ad
late
hpi
suggest
interfer
viral
attach
entri
step
larg
complet
within
hpi
studi
need
determin
exact
stage
atanyl
blue
prl
act
could
interfer
capsid
transport
nuclear
pore
releas
viral
dna
circular
dna
derepress
miep
ie
transcriptiontransl
two
line
evid
suggest
nonspecif
effect
atanyl
blue
viral
dna
synthesi
rna
transcript
protein
synthesi
rule
first
barnard
et
al
measur
effect
atanyl
blue
cellular
dna
rna
protein
synthesi
observ
ic
barnard
et
al
second
atanyl
blue
prl
ad
hpi
reduc
viral
dna
level
infecti
viru
yield
dpi
fig
hpi
viral
dna
synthesi
transcriptiontransl
late
protein
necessari
assembl
viral
progeni
begin
inhibit
either
activ
start
hpi
substanti
reduc
viral
yield
evidenc
potent
inhibitori
effect
ganciclovir
ad
even
hpi
fig
hsiang
ho
show
emodin
inhibit
nucleas
activ
recombin
alkalin
nucleas
vitro
hsiang
ho
infer
emodin
may
inhibit
replic
target
nucleas
activ
hypothesi
confirm
map
emodin
resist
amino
acid
chang
moreov
recent
report
indic
genet
inactiv
nucleas
activ
littl
effect
replic
cell
cultur
fujii
et
al
cmv
alkalin
nucleas
import
effici
replic
cell
cultur
null
mutant
sever
replic
defici
kuchta
et
al
howev
import
nucleas
activ
yet
evalu
target
mutat
activ
site
thu
possibl
atanyl
blue
prl
inhibit
cmv
replic
inhibit
molecular
model
studi
conduct
gain
insight
structur
featur
ligand
protein
activesit
allow
inhibit
activ
atanyl
blue
prl
acid
blue
compound
dock
activ
site
model
built
use
kshvsox
pdb
templat
kuchta
et
al
favor
bind
mode
compound
fig
concord
dna
substrat
ligand
show
signific
interact
activ
site
residu
previous
verifi
use
mutagenesi
kuchta
et
al
sulfon
group
interact
analog
interact
made
phosphat
group
oxygen
coordin
put
activ
site
metal
occupi
posit
analog
group
mesitylen
moieti
atanyl
blue
prl
form
favor
hydrophob
interact
contrast
nphenylacetamid
moieti
acid
blue
form
weaker
hydrophob
interact
owe
polar
amid
substitut
phenyl
ring
lipophil
potenti
surfac
map
ligand
within
protein
activ
site
clearli
show
favor
hydrophobichydrophob
complementar
atanyl
blue
prl
compar
unfavor
polarhydrophob
complementar
acid
blue
anoth
key
noncoval
interact
observ
stack
interact
guanidinium
ion
aromat
substitu
atanyl
blue
prl
stack
interact
stabil
electrondon
substitu
phenyl
ring
addit
favor
interact
observ
atanyl
blue
prl
may
explain
better
inhibit
profil
compar
acid
blue
mechan
mediat
nucleas
inhibit
requir
confirm
map
atanyl
blue
prl
resist
mutat
atanyl
blue
prl
inhibit
cmv
replic
inhibit
result
would
indic
present
function
import
earli
infect
consist
low
level
observ
infect
cell
earli
hpi
adam
et
al
coincid
time
window
atanyl
blue
prl
activ
howev
role
earli
late
cmv
replic
would
contrast
propos
role
alkalin
nucleas
late
life
cycl
support
recombinationdepend
dna
replic
reuven
et
al
dna
packag
capsid
format
nuclear
egress
martinez
et
al
porter
stow
shao
et
al
weller
et
al
possibl
serv
differ
function
replic
respect
virus
also
possibl
atanyl
blue
prl
inhibit
nucleas
activ
coincident
true
mechan
cmv
inhibit
involv
differ
viral
cellular
target
import
earli
cmv
replic
anthraquinon
atanyl
blue
prl
inhibit
cmv
replic
cell
cultur
act
earli
cmv
replic
cycl
block
ie
protein
synthesi
time
addit
studi
suggest
act
viral
entri
consequ
atanyl
blue
prl
may
use
pharmacolog
probe
better
understand
postentri
molecular
event
culmin
robust
ie
transcriptiontransl
atanyl
blue
prl
may
also
use
lead
structur
antivir
drug
discoverydevelop
atanyl
blue
prl
also
inhibit
nucleas
activ
cmv
vitro
remain
establish
whether
anticmv
activ
mediat
inhibit
howev
find
would
implic
nucleas
import
factor
earli
event
determin
fate
infect
cell
would
signal
profound
revis
understand
herpesviru
alkalin
nucleas
function
viral
replic
anthraquinon
atanyl
blue
prl
inhibit
human
cytomegaloviru
replic
block
viral
replic
appear
earli
entri
substanti
reduc
viral
immedi
earli
gene
express
vitro
atanyl
blue
prl
inhibit
nucleas
activ
purifi
viral
alkalin
nucleas
antivir
activ
atanyl
blue
prl
may
manifest
inhibit
nucleas
activ
structur
compound
use
antivir
activ
emodin
blue
line
determin
infect
confluent
monolay
plate
luciferasetag
cmv
moi
presenc
increas
concentr
emodin
five
day
supernat
transfer
plate
contain
fresh
monolay
h
later
cultur
lyse
luciferas
activ
determin
measur
viru
transfer
cultur
supernat
cytotox
red
line
determin
incub
replic
uninfect
cultur
emodin
five
day
determin
luciferas
activ
measur
cell
viabil
use
celltiterglo
assay
b
antivir
activ
indic
compound
determin
describ
panel
c
cytotox
indic
compound
determin
describ
panel
result
panel
b
c
graph
togeth
illustr
differ
antivir
activ
blue
cytotox
red
atanyl
blue
prl
plate
contain
confluent
monolay
cell
infect
moi
gfptag
cmv
presenc
increas
concentr
atanyl
blue
prl
four
dpi
gfp
fluoresc
determin
measur
viral
gene
express
b
experi
conduct
use
moi
cell
ten
initi
infect
gfp
fluoresc
determin
everi
two
day
measur
viral
spread
cell
initi
uninfect
data
shown
dpi
c
plate
contain
confluent
monolay
cell
infect
moi
absenc
presenc
atanyl
blue
prl
gfpposit
cell
mark
photograph
six
dpi
twoday
interv
thereaft
repres
imag
shown
thirtytwo
replic
well
contain
cell
infect
inoculum
suffici
infect
well
absenc
inhibitor
replic
set
well
infect
treat
increas
concentr
atanyl
blue
prl
day
well
contain
gfpposit
cell
score
undergon
success
viral
infect
spread
number
posit
well
convert
gfp
posit
well
respect
hpi
cultur
maintain
without
medium
chang
five
dpi
b
experi
repeat
atanyl
blue
prl
ad
final
concentr
hpi
experi
preincub
cell
group
consist
well
preincub
h
atanyl
blue
prl
wash
three
time
medium
infect
viru
incub
without
atanyl
blue
prl
five
day
preincub
viru
group
higher
concentr
viru
inoculum
preincub
atanyl
blue
prl
h
dilut
medium
ad
cell
incub
without
atanyl
blue
prl
five
day
viru
yield
determin
five
dpi
transfer
cultur
supernat
fresh
monolay
quantit
luciferas
activ
incub
h
cell
lysat
prepar
indic
dpi
analyz
immunoblot
use
antibodi
specif
imag
composit
separ
gel
treat
untreat
sampl
given
day
analyz
gel
quantit
compar
howev
sampl
differ
day
analyz
separ
gel
therefor
accur
reflect
quantit
chang
time
b
cell
infect
moi
replic
cultur
treat
inhibitor
